Globally, there are more than 70 million people living with chronic hepatitis C virus (HCV), and an estimated 257 million people living with hepatitis B virus (HBV), both of which causes significant morbidity and mortality as it can lead to liver damage, liver cancer and liver failure. Despite having the biomedical tools to eliminate HCV and HBV, viral hepatitis causes 1.34 million deaths globally each year.
The EILF Centres of Excellence in Viral Hepatitis Elimination are intended to be distinguished providers of thought leadership, and act as knowledge hubs, fostering exchanges of research, training, good practices and lessons learnt. EILF works in close collaboration with a wide range of partners, including experts and leaders in the field of viral hepatitis. Through the initiative EILF aims to create a community which will serve as a global network for sharing knowledge and best practice and as a reference points for others to follow
Working in partnership with the public and private sector to achieve our goal of eliminating viral hepatitis.